Literature DB >> 14599788

The C-terminal half-fragment of the Sendai virus C protein prevents the gamma-activated factor from binding to a gamma-activated sequence site.

Bin Gotoh1, Takayuki Komatsu, Kenji Takeuchi, Junko Yokoo.   

Abstract

Sendai virus C protein associates with the signal transducer and activator of transcription (STAT) 1 and inhibits the interferon (IFN) response. We report a molecular basis for the anti-IFN-gamma mechanism of Sendai virus. The C-terminal half-fragment of the C protein (D1) retains both the STAT1-binding and the anti-IFN-gamma abilities comparable to those of the full-size C. IFN-gamma stimulation generates phosphorylated-STAT1 even in the presence of the C or the D1. The phosphorylated-STAT1 generated in the D1-expressing cells forms an aberrant complex, which does not bind to a gamma-activated sequence (GAS) probe. Purified D1, indeed, inhibits in vitro the binding of the phosphorylated-STAT1 dimer to the GAS probe. The D1, however, binds to the STAT1 N-terminal domain, but not the DNA binding domain. These results suggest the possibility that the C protein prevents the gamma-activated factor from binding to GAS elements through its interaction with the STAT1 N-terminal domain.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14599788     DOI: 10.1016/s0042-6822(03)00590-7

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

Review 1.  Molecular Mechanisms of Innate Immune Inhibition by Non-Segmented Negative-Sense RNA Viruses.

Authors:  Srirupa Chatterjee; Christopher F Basler; Gaya K Amarasinghe; Daisy W Leung
Journal:  J Mol Biol       Date:  2016-07-31       Impact factor: 5.469

2.  C Protein is Essential for Canine Distemper Virus Virulence and Pathogenicity in Ferrets.

Authors:  Oliver Siering; Bevan Sawatsky; Christian K Pfaller
Journal:  J Virol       Date:  2020-11-25       Impact factor: 5.103

Review 3.  Type I and Type II Interferon Antagonism Strategies Used by Paramyxoviridae: Previous and New Discoveries, in Comparison.

Authors:  Giuseppe Pisanelli; Ugo Pagnini; Giuseppe Iovane; Adolfo García-Sastre
Journal:  Viruses       Date:  2022-05-21       Impact factor: 5.818

4.  The nucleocytoplasmic rabies virus P protein counteracts interferon signaling by inhibiting both nuclear accumulation and DNA binding of STAT1.

Authors:  Aurore Vidy; Jamila El Bougrini; Mounira K Chelbi-Alix; Danielle Blondel
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

5.  Measles virus phosphoprotein gene products: conformational flexibility of the P/V protein amino-terminal domain and C protein infectivity factor function.

Authors:  Patricia Devaux; Roberto Cattaneo
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  Structural Basis of the Inhibition of STAT1 Activity by Sendai Virus C Protein.

Authors:  Kosuke Oda; Yasuyuki Matoba; Takashi Irie; Ryoko Kawabata; Masaya Fukushi; Masanori Sugiyama; Takemasa Sakaguchi
Journal:  J Virol       Date:  2015-09-02       Impact factor: 5.103

7.  Sendai virus C protein plays a role in restricting PKR activation by limiting the generation of intracellular double-stranded RNA.

Authors:  Kenji Takeuchi; Takayuki Komatsu; Yoshinori Kitagawa; Kiyonao Sada; Bin Gotoh
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

8.  Structural analysis of the STAT1:STAT2 heterodimer revealed the mechanism of Sendai virus C protein-mediated blockade of type 1 interferon signaling.

Authors:  Kosuke Oda; Takashi Oda; Yasuyuki Matoba; Mamoru Sato; Takashi Irie; Takemasa Sakaguchi
Journal:  J Biol Chem       Date:  2017-10-04       Impact factor: 5.157

9.  Clustered basic amino acids of the small sendai virus C protein Y1 are critical to its RAN GTPase-mediated nuclear localization.

Authors:  Takashi Irie; Asuka Yoshida; Takemasa Sakaguchi
Journal:  PLoS One       Date:  2013-08-09       Impact factor: 3.240

10.  Rinderpest virus blocks type I and type II interferon action: role of structural and nonstructural proteins.

Authors:  Sambit K Nanda; Michael D Baron
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.